GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (TSX:GUD) » Definitions » Operating Margin %

Knight Therapeutics (TSX:GUD) Operating Margin % : -0.11% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Knight Therapeutics's Operating Income for the three months ended in Dec. 2023 was C$-0.1 Mil. Knight Therapeutics's Revenue for the three months ended in Dec. 2023 was C$74.2 Mil. Therefore, Knight Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 was -0.11%.

The historical rank and industry rank for Knight Therapeutics's Operating Margin % or its related term are showing as below:

TSX:GUD' s Operating Margin % Range Over the Past 10 Years
Min: -1378.63   Med: -36.47   Max: 1.94
Current: 1.94


TSX:GUD's Operating Margin % is ranked worse than
61.67% of 1020 companies
in the Drug Manufacturers industry
Industry Median: 6.385 vs TSX:GUD: 1.94

Knight Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Knight Therapeutics's Operating Income for the three months ended in Dec. 2023 was C$-0.1 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was C$6.4 Mil.


Knight Therapeutics Operating Margin % Historical Data

The historical data trend for Knight Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Knight Therapeutics Operating Margin % Chart

Knight Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -26.67 -15.04 -5.27 -5.81 1.94

Knight Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.20 6.82 -0.12 1.14 -0.11

Competitive Comparison of Knight Therapeutics's Operating Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Knight Therapeutics's Operating Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Knight Therapeutics's Operating Margin % falls into.



Knight Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Knight Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=6.37 / 328.199
=1.94 %

Knight Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-0.083 / 74.197
=-0.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Knight Therapeutics  (TSX:GUD) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Knight Therapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Knight Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Knight Therapeutics (TSX:GUD) Business Description

Traded in Other Exchanges
Address
3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Ltin America and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.
Executives
Sime Armoyan 10% Security Holder

Knight Therapeutics (TSX:GUD) Headlines

No Headlines